Limited Eligibility for New Alzheimer's Drugs Leaves Many Patients Without Treatment Options
Only a small percentage of people with early-stage Alzheimer's disease are eligible for new monoclonal antibody treatments, according to researchers. The eligibility criteria for clinical trials of drugs like aducanumab and lecanemab result in a limited number of individuals meeting the requirements for treatment. Factors such as chronic health conditions and brain scan abnormalities common in older adults contribute to the low eligibility rate. Experts emphasize the need for further research in larger and more diverse populations to determine the safety and efficacy of these treatments for a broader range of people.
